48.3 Pediatric Enuresis & Encopresis

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

48.3 Pediatric Enuresis & Encopresis

Key Takeaways Explain This Topic AI

Nocturnal enuresis is defined as involuntary voiding during sleep in children aged >=5 years (chronological and developmental age) at least twice per week for >=3 consecutive months; primary monosymptomatic enuresis is a developmental delay in nocturnal vasopressin secretion, functional bladder capacity, and sleep arousal threshold.

Urinalysis is the mandatory initial diagnostic laboratory investigation for every child presenting with enuresis to decisively exclude glucosuria (Type 1 diabetes mellitus), proteinuria (renal parenchymal disease), leukocyte esterase/nitrites (urinary tract infection), and low specific gravity (diabetes insipidus).

The enuresis alarm is the first-line definitive non-pharmacologic intervention for monosymptomatic nocturnal enuresis, providing the highest long-term cure rate (>60-70%) and lowest relapse rate; oral desmopressin (DDAVP) is first-line pharmacotherapy for rapid situational control, requiring strict fluid restriction (no fluids 1 hour before to 8 hours after dosing) to prevent life-threatening dilutional hyponatremic seizures.

Greater than 95% of pediatric encopresis is retentive fecal incontinence secondary to chronic constipation (paradoxical overflow incontinence), wherein voluntary stool withholding causes progressive rectal dilation, blunted sensory perception, megarectum, and involuntary leakage of liquid stool around a rock-hard fecaloma.

Management of retentive encopresis requires a structured 3-phase protocol: Phase 1 acute disimpaction with high-dose oral Polyethylene Glycol (PEG 3350 1-1.5 g/kg/day for 3-6 days), Phase 2 daily maintenance osmotic laxatives for a MANDATORY 6 TO 12 MONTHS to allow the stretched rectum to remodel and recover muscle tone, and Phase 3 scheduled unhurried postprandial toilet sitting (5-10 minutes twice daily) using the gastrocolic reflex with footstool support.

Last updated: September 2026

Pediatric Nocturnal Enuresis: Definitions, Pathophysiology & Classification

Nocturnal enuresis (bedwetting) is one of the most prevalent developmental elimination problems in pediatric primary care, affecting approximately 15% of 5-year-old children, 5% of 10-year-olds, and 1% to 2% of adolescents. It carries an immense psychosocial burden, generating profound feelings of shame, social isolation, guilt, and low self-esteem, while frequently causing family conflict.

Diagnostic Criteria (DSM-5 & ICCS)

According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and the International Children's Continence Society (ICCS), nocturnal enuresis is defined by:

Involuntary or intentional voiding of urine into bed or clothes during sleep;

Chronological and developmental age of at least 5 years (prior to age 5, nocturnal incontinence is developmentally normal);

Frequency of at least twice per week for a minimum of 3 consecutive months , or causing clinically significant distress or social/academic impairment;

Not attributable to the direct physiological effects of a substance (such as a diuretic) or a general medical condition (such as neurogenic bladder, spina bifida, or diabetes mellitus).

Clinical Classification Schemes CLASSIFICATION OF NOCTURNAL ENURESIS

• Classification Axis Subtype Core Pathophysiologic Characteristics
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Symptom Profile Axis Monosymptomatic Enuresis occurring EXCLUSIVELY during sleep;
• Nocturnal Enuresis (MNE) NO daytime lower urinary tract symptoms (LUTS);

accounts for >80% of all enuretic children.

• Non-Monosymptomatic Nocturnal enuresis accompanied by DAYTIME
• Enuresis (NMNE) urinary symptoms: daytime frequency (>=8x/day),
• urgency, holding maneuvers (Vincent's curtsy),

daytime wetting/leakage, dysuria, or hesitancy.

• ─────────────────────────────────────────────────────────────────────────────────────────────
• Chronological Onset Axis Primary Enuresis Child has NEVER achieved nighttime dryness for
• a continuous period of at least 6 months;

represents a developmental-maturational delay.

• Secondary Enuresis Bedwetting restarts AFTER at least 6 months
• of established continuous nighttime continence;
• strongly indicates an identifiable medical,

psychological, or environmental trigger.

• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• The Pathophysiologic Triad of Primary Monosymptomatic Enuresis

Primary monosymptomatic nocturnal enuresis is not a behavioral or psychiatric disorder; rather, it represents a maturational developmental lag involving three interacting physiological mechanisms:

Nocturnal Polyuria (Blunted Vasopressin Surge) : Under normal physiological conditions, the anterior pituitary releases an exaggerated nocturnal surge of Arginine Vasopressin (Antidiuretic Hormone [ADH]), concentrating urine and reducing nocturnal urine production by >50%. Children with primary enuresis lack this nocturnal ADH surge, producing massive volumes of dilute urine overnight that overwhelm normal bladder capacity.

Nocturnal Low Functional Bladder Capacity / Detrusor Overactivity : Uninhibited detrusor contractions occur during sleep, or the child's functional nocturnal bladder capacity is significantly lower than daytime capacity.

Sleep Arousal Failure : The central nervous system fails to recognize signals of bladder distension during sleep. Although historically labeled "deep sleepers," electroencephalographic studies reveal that these children have a high arousal threshold; when detrusor contractions occur, the locus coeruleus fails to arouse the child to wakefulness, resulting in reflexive bladder emptying in bed.

Genetic Predisposition : Strong autosomal dominant inheritance with high penetrance. If one parent was enuretic, a child has a 44% risk of enuresis; if both parents were enuretic, the risk climbs to 77% . Several genetic loci have been mapped to chromosomes 12q and 13q.

• Diagnostic Evaluation of the Enuretic Child
• Evaluating Secondary Enuresis: The Red Flag Triggers

When a child develops secondary enuresis (bedwetting resuming after >=6 months of continence), clinicians must conduct a targeted search for specific underlying organic etiologies:

Type 1 Diabetes Mellitus (T1D) : Severe osmotic diuresis triggered by hyperglycemia. Presents with secondary enuresis accompanied by polydipsia, polyuria, polyphagia, and rapid weight loss .

Urinary Tract Infection (UTI) : Acute dysuria, new-onset daytime urgency, frequency, foul-smelling urine, or fever.

Obstructive Sleep Apnea (OSA) : Severe adenotonsillar hypertrophy producing nocturnal airway obstruction. Hypoxemia and increased negative intrathoracic pressure cause cardiac atrial stretch, triggering the release of Atrial Natriuretic Peptide (ANP) . ANP inhibits vasopressin and stimulates marked renal sodium and water excretion, producing nocturnal polyuria and enuresis. Adenotonsillectomy cures enuresis in up to 60% of these children.

Chronic Constipation / Fecal Impaction : A distended fecaloma in the rectum physically compresses the posterior bladder wall and bladder neck, triggering uninhibited detrusor contractions and reducing functional bladder capacity.

Psychological Stressors / Trauma : Birth of a new sibling, parental divorce, family bereavement, moving homes, school bullying, or sexual abuse .

Spinal Dysraphism / Tethered Cord Syndrome : Congenital caudal tethering of the conus medullaris causing neurogenic bladder dysfunction.

The Mandatory Diagnostic Laboratory Workup DIAGNOSTIC WORKUP FOR PEDIATRIC ENURESIS

• Diagnostic Element Clinical Finding / Target Diagnostic Significance
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• Clean-Catch Midstream • Glucosuria • Rules out Type 1 Diabetes Mellitus
• Urinalysis • Leukocyte esterase / Nitrites • Rules out active Urinary Tract Infection
• (MANDATORY IN ALL CASES) • Proteinuria • Identifies glomerulopathy / renal disease
• Specific Gravity (low <1.005) • Evaluates Diabetes Insipidus / water load

• Voiding Diary 48- to 72-hour record of fluid intake, Quantifies bladder capacity, confirms
• daytime void frequency, urine volume, daytime continence vs hidden LUTS

• Physical Examination • Blood Pressure • Identifies renal hypertension
• Abdominal Palpation • Detects hard suprapubic fecal mass
• Midline Lumbosacral Spine • Screens for occult spinal dysraphism
• Neurological Lower Extremities • L4-S1 reflexes, tone, gait, anal wink
• ═════════════════════════════════════════════════════════════════════════════════════════════════

Important

URINALYSIS IS THE MANDATORY INITIAL LABORATORY TEST A clean-catch midstream urinalysis (dipstick and microscopic examination) is mandatory in EVERY pediatric patient presenting with enuresis . It is inexpensive, non-invasive, and instantly excludes life-threatening metabolic disorders (diabetic ketoacidosis from Type 1 diabetes), acute infection, and intrinsic nephropathy.

Physical Examination Details :

Lumbosacral Spine Examination : Carefully inspect the midline skin overlying the lower spine for cutaneous markers of occult spinal dysraphism (spina bifida occulta, tethered cord): a sacral dimple (especially if >5 mm in diameter, located >2.5 cm above the anal verge, or with a concealed base), hair tuft ("faun tail") , subcutaneous lipoma, hemangioma, or asymmetric gluteal cleft.

Neurological Examination : Test deep tendon reflexes in the lower extremities (patellar L4, Achilles S1), assess muscle tone and strength, observe gait and toe-walking, and test perineal sensation and the anal wink reflex (S2-S4) .

Genital Examination : Check for urethral meatal stenosis in boys, labial adhesions in girls, and signs of sexual abuse.

When Imaging is Indicated : In an uncomplicated child aged >=5 years with primary monosymptomatic nocturnal enuresis, a completely normal physical examination, and a negative urinalysis, renal ultrasound, voiding cystourethrogram (VCUG), and spinal MRI are NOT indicated . Imaging is reserved strictly for children with daytime LUTS, recurrent febrile UTIs, abnormal spinal/neurological findings, or refractory secondary enuresis.

Management of Monosymptomatic Nocturnal Enuresis

Management follows a stepwise, evidence-based paradigm combining behavioral conditioning, lifestyle modifications, and targeted pharmacotherapy.

Step 1: Education, Demystification & Parental Reassurance

Demystify the Condition : Educate both parents and child that enuresis is a common, involuntary developmental delay with a strong genetic basis, not a behavioral defiance, laziness, or willful misconduct.

ELIMINATE PUNITIVE MEASURES : Shaming, blaming, or punishing the child is completely counterproductive, provokes deep psychological distress, worsens nocturnal wetting, and increases the risk of emotional disorders.

Fluid Guidance & Sleep Hygiene :

• Provide 70% to 80% of the child's daily fluid requirements between morning and late afternoon;
• Restrict evening fluids during the 2 hours preceding bedtime;
• Eliminate evening caffeinated beverages (colas, teas) and sugary drinks, which act as osmotic diuretics;
• Establish a routine of mandatory voiding immediately before lights-out ;

Ensure easy, illuminated access to the bathroom at night (nightlights, bedside stepstool).

Motivational Strategies : Use positive sticker charts that reward the child for adherence to the nighttime routine (e.g., stopping fluids, emptying bladder before bed) rather than dry nights, preventing the child from feeling like a failure on wet mornings.

Step 2: First-Line Definitive Behavioral Therapy: The Enuresis Alarm THE ENURESIS ALARM: CLINICAL ATTRIBUTES

• Feature Clinical Details
• ═════════════════════════════════════════════════════════════════════════════════════════════
• Mechanism of Action Classical Pavlovian conditioning: a moisture sensor attached to underwear
• or pajamas triggers a loud auditory and/or vibratory alarm at the FIRST

drop of urine, provoking external sphincter contraction and awakening the child.

Efficacy Profile HIGHEST LONG-TERM CURE RATE (>60% to 70%) of all interventions;

LOWEST RELAPSE RATE (<10% to 15%) upon successful completion.

• Treatment Protocol Requires a motivated child (typically age >=6-7 years) and dedicated parents;
• must be used CONSISTENTLY EVERY NIGHT for a MINIMUM OF 2 TO 3 MONTHS;

continue until achieving 14 CONSECUTIVE DRY NIGHTS before discontinuing.

═════════════════════════════════════════════════════════════════════════════════════════════

The enuresis alarm is the treatment of choice for long-term cure .

Practical Tip: During the initial 2 to 4 weeks, the child will rarely awaken spontaneously to the alarm. A parent must sleep in the same room to awaken the child, escort them to the toilet to finish voiding, change the wet sheets together, and reset the alarm.

Step 3: First-Line Pharmacotherapy: Desmopressin (DDAVP)

Desmopressin acetate (1-deamino-8-D-arginine vasopressin) is a synthetic structural analogue of human vasopressin that selectively binds to V2 receptors on renal collecting duct tubular cells, increasing water reabsorption and dramatically concentrating urine volume.

Indications : Rapid, situational, short-term reduction in bedwetting—ideal for sleepovers, summer camps, vacations, or when alarm therapy has failed or family dynamics preclude alarm use.

Formulation & Dosing : Oral tablet (0.2 mg taken orally 1 hour before bedtime, titrated up to 0.4 mg or maximum 0.6 mg if necessary) or orally disintegrating sublingual melt (120 mcg up to 240 mcg).

Contrast with Alarm : Desmopressin acts immediately (night 1), but upon discontinuation, relapse rates exceed 60% to 70% because it treats the symptom rather than curing the underlying arousal deficit.

Caution

CRITICAL BLACK BOX SAFETY WARNING: HYPONATREMIC SEIZURES Intranasal desmopressin is STRICTLY CONTRAINDICATED for enuresis due to erratic mucosal absorption and an unacceptably high risk of severe dilutional hyponatremia and fatal seizures. Only ORAL formulations are approved.

MANDATORY FLUID RESTRICTION PROTOCOL :

If a child ingests desmopressin while continuing to drink fluids, free water is retained while urinary output ceases, precipitating acute dilutional hyponatremia, water intoxication, cerebral edema, generalized seizures, coma, and death .

Clinicians must provide explicit written instructions: the child must consume NO MORE THAN 8 OUNCES (240 mL) OF FLUID starting 1 hour before desmopressin administration, and FLUIDS MUST BE STRICTLY WITHHELD FOR 8 FULL HOURS AFTER DOSING .

Desmopressin must be immediately discontinued during acute febrile illnesses, vomiting, or diarrhea.

Step 4: Second-Line Medications & Refractory Strategies

Imipramine (Tricyclic Antidepressant) : Historical second-line agent. Mechanism involves weak peripheral anticholinergic bladder relaxation, alpha-adrenergic bladder neck contraction, and alteration of sleep architecture. Dosed at 25 to 50 mg at bedtime. Major Safety Warning: Narrow therapeutic index and high cardiotoxicity in accidental overdose (fatal ventricular arrhythmias, heart block, refractory seizures). Requires a baseline ECG (normal QTc interval) and childproof locked storage. Rarely used today due to toxicity.

Anticholinergic Agents (Oxybutynin) : Indicated exclusively when enuresis is accompanied by detrusor overactivity / daytime non-monosymptomatic symptoms (NMNE) ; ineffective as monotherapy for monosymptomatic enuresis.

Pediatric Encopresis (Fecal Incontinence) & Overflow Pathophysiology

Encopresis is the repeated, voluntary or involuntary passage of feces into inappropriate places (such as underwear, clothing, or the floor) in a child with a chronological and developmental age of at least 4 years .

• Diagnostic Criteria (DSM-5)
• Passage of feces into inappropriate places at least once a month for at least 3 consecutive months ;
• Chronological and developmental age of at least 4 years ;

Not attributable exclusively to the physiological effects of a substance (e.g., laxatives) or a primary organic medical condition (such as Hirschsprung disease, anal stenosis, spinal cord trauma, or celiac disease).

Classification: Retentive vs. Non-Retentive RETENTIVE VS NON-RETENTIVE ENCOPRESIS

• Feature Retentive Encopresis (> 95% of Cases) Non-Retentive Encopresis (< 5% of Cases)
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Constipation Status PRESENT: Severe chronic constipation ABSENT: Normal bowel habit frequency;
• with fecal retention and megarectum no hard stools or fecal impaction

Pathophysiologic PARADOXICAL OVERFLOW INCONTINENCE: BEHAVIORAL / EMOTIONAL DYSREGULATION:

• Mechanism liquid stool seeps around hard mass oppositional defiant disorder, stress,
• conduct disorder, sexual abuse

• Physical Exam Palpable rock-hard lower quadrant mass; Normal abdominal and rectal exam;
• dilated rectal vault filled with feces rectum completely empty of feces

• Primary Therapy Laxative disimpaction followed by Behavioral and family psychotherapy;
• prolonged daily maintenance laxatives NO laxative therapy indicated
• ═════════════════════════════════════════════════════════════════════════════════════════════════════
• Pathophysiology of Retentive Encopresis: The Vicious Withholding Cycle

Over 95% of all pediatric encopresis is Retentive Encopresis with Constipation (Paradoxical Fecal Overflow Incontinence) :

The Precipitating Trigger : Defecation becomes painful due to a large, hard stool, painful anal fissure, acute diaper dermatitis, coercive toilet training, or reluctance to use unhygienic school restrooms.

Voluntary Stool Withholding : To avoid pain, the child actively contracts the external anal sphincter and gluteal muscles whenever the urge to defecate arises ("withholding posturing": stiffening legs, standing on tiptoes, crossing legs, rocking, hiding in corners).

Rectal Distension & Water Absorption : Stool accumulates in the rectal vault. The colonic mucosa continues to absorb water, transforming the retained stool into a rock-hard, massive fecaloma.

Rectal Desensitization & Megarectum : Chronic mechanical distension stretches the rectal wall, blunting the mechanoreceptors that generate the rectal fullness sensation and the urge to defecate. The rectal compliance increases dramatically, producing an atonic megarectum .

Paradoxical Overflow Incontinence : Semisolid and liquid chyme from the proximal colon reaches the obstructed rectal vault. Unable to pass through the rock-hard impaction, liquid stool trickles around the periphery of the fecaloma and leaks continuously and involuntarily into the child's underwear .

Warning

THE CARDINAL DIAGNOSTIC PITFALL: MISTAKEN FOR CHRONIC DIARRHEA Parents (and inexperienced clinicians) almost universally mistake the foul-smelling liquid stool in the underwear for "chronic diarrhea," "gastroenteritis," or "poor personal hygiene." Inadvertently prescribing antidiarrheal medications (such as loperamide) is catastrophic malpractice that severely worsens the fecal impaction, potentially precipitating stercoral ulceration or bowel perforation.

Comprehensive 3-Phase Management Protocol for Encopresis

Successful management of retentive encopresis requires a rigorous, protocolized 3-phase treatment strategy combining medical disimpaction, prolonged maintenance laxatives, and behavioral retraining. THE THREE-PHASE PROTOCOL FOR RETENTIVE ENCOPRESIS

• Protocol Phase Primary Objective Guideline Clinical Regimen
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• Phase 1: Evacuate the rock-hard fecaloma High-Dose Oral Polyethylene Glycol
• Acute Disimpaction from the rectal vault and colon (PEG 3350): 1.0 to 1.5 g/kg/day
• (Duration: 3 to 6 consecutive days) (max 100 g/day) divided daily

Phase 2: Keep rectum empty to allow stretched Maintenance Oral PEG 3350:

• Maintenance Laxatives rectal musculature to shrink and 0.4 to 0.8 g/kg/day daily titrated
• regain normal sensory-motor tone to achieve 1-2 soft stools daily;
• MANDATORY DURATION: 6 TO 12 MONTHS

• Phase 3: Re-establish physiological unhurried Scheduled postprandial toilet sitting
• Behavioral Modification & defecation utilizing gastrocolic 5-10 minutes twice daily (15-30 min
• Postural Ergonomics reflex; eliminate pelvic floor spasm after meals) with footstool support
• ═════════════════════════════════════════════════════════════════════════════════════════════════
• Phase 1: Acute Disimpaction

First-Line Regimen : High-dose oral Polyethylene Glycol 3350 without electrolytes (PEG 3350; Miralax) dosed at 1.0 to 1.5 g/kg/day (up to a maximum of 100 g/day) for 3 to 6 consecutive days .

PEG 3350 is an inert, non-absorbable osmotic laxative that retains water in the colonic lumen, softening the fecal mass and promoting spontaneous, painless evacuation without causing electrolyte derangements, cramping, or mucosal irritation.

Rectal Therapies : Pediatric hypertonic saline enemas (Fleet enemas), mineral oil enemas, or bisacodyl suppositories can be used as alternatives or adjuncts if oral therapy is not tolerated or vomiting occurs. However, oral PEG 3350 is strongly preferred because rectal interventions are emotionally traumatic, invasive, and reinforce fears of anal manipulation.

Phase 2: Maintenance Laxative Therapy (The Critical Extended Duration)

Following successful disimpaction, the child must immediately transition to daily maintenance laxative therapy with oral PEG 3350 at 0.4 to 0.8 g/kg/day .

The dose is titrated every few days to ensure the passage of 1 to 2 soft, painless, pudding-consistency stools daily .

Important

THE 6-TO-12-MONTH MAINTENANCE MANDATE The single most common cause of treatment failure and encopresis relapse is premature discontinuation of maintenance laxative therapy by parents who stop the medication as soon as daily soiling stops.

When a child's rectum has been chronically distended for months, the rectal smooth muscle is thinned, atonic, and insensitive. It takes a minimum of 6 to 12 consecutive months of keeping the rectum continuously empty for the rectal wall to remodel, regain normal tone, and restore mechanoreceptor sensory perception. Maintenance therapy must continue uninterrupted for at least 6 months before any attempt at very gradual weaning.

Phase 3: Behavioral Modification & Postural Ergonomics

Medical therapy alone fails if withholding behaviors are not simultaneously extinguished through structured behavioral retraining:

Scheduled, Unhurried Postprandial Toilet Sits :

The child must sit on the toilet for 5 to 10 minutes twice daily, consistently timed 15 to 30 minutes after meals (typically breakfast and dinner).

This harnesses the physiologic gastrocolic reflex (gastric distension by food triggers reflexive colonic mass peristalsis).

Postural Ergonomics (The Footstool) :

When a child sits on an adult toilet with dangling feet, the pelvic floor muscles (specifically the puborectalis sling) remain contracted, creating an acute anorectal angle that obstructs defecation.

A footstool (such as a Squatty Potty or stepstool) must be placed under the child's feet so the soles rest flat and the knees are elevated slightly higher than the hips (hip flexion >90°) . This relaxes the puborectalis muscle, straightens the anorectal angle, and permits effortless evacuation without straining.

Positive Reinforcement Systems : Implement a calendar or sticker chart that rewards effort and compliance with toilet sitting , NOT stool production or clean underwear. Children must NEVER be reprimanded, punished, or shamed for accidental soiling, as anxiety directly triggers pelvic floor dyssynergia.

Dietary Counseling : Gradual introduction of age-appropriate dietary fiber (calculated as age in years + 5 grams per day ) and abundant water consumption.

Loading diagram... Comprehensive Triage and Stepwise Management of Pediatric Elimination Disorders